Table.
Patients' characteristics and laboratory results
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | Female | Male | Female | Female | Female | Female | Female | Female | Female | Male | |
| Age, years | 82 | 74 | 73 | 77 | 82 | 71 | 70 | 39 | 70 | 64 | |
| Biologic treatment | Rituximab | Rituximab | Rituximab | Rituximab | Rituximab | Rituximab | Rituximab | Rituximab | Rituximab | Rituximab | |
| Dose of last rituximab therapy | 500 mg | 500 mg | 500 mg (× 2) | 1000 mg | 1000 mg | 500 mg (× 2) | 500 mg | 500 mg (× 2) | 500 mg | 1000 mg | |
| Associated conventional synthetic DMARDs | NA | Oral methotrexate 20 mg per week | Subcutaneous methotrexate 15 mg per week | NA | NA | NA | NA | Subcutaneous methotrexate 25 mg per week | Subcutaneous methotrexate 12·5 mg per week | Subcutaneous methotrexate 25 mg per week | |
| Corticosteroids | Prednisone 10 mg per day | Prednisone 10 mg per day | NA | NA | NA | NA | NA | Prednisone 20 mg per day | NA | NA | |
| Condition | Rheumatoid arthritis | Rheumatoid arthritis | Rheumatoid arthritis | Rheumatoid arthritis | Rheumatoid arthritis | Stiff-person syndrome | Rheumatoid arthritis | Rheumatoid arthritis | Rheumatoid arthritis | Rheumatoid arthritis | |
| Number of anterior rituximab therapy cycles | 5 | 5 | 6 | 11 | 4 | 2 | 14 | 2 | 12 | 3 | |
| Vaccine administered for first two doses | mRNA-1273 (Moderna) | mRNA-1273 (Moderna) | mRNA-1273 (Moderna) | mRNA-1273 (Moderna) | BNT162b2 (Pfizer–BioNTech) | BNT162b2 (Pfizer–BioNTech) | BNT162b2 (Pfizer–BioNTech) | BNT162b2 (Pfizer–BioNTech) | BNT162b2 (Pfizer-–BioNTech) | ChAdOx1 nCoV-19 (Oxford–AstraZeneca) | |
| Vaccine administered as third dose | mRNA-1273 (Moderna) | mRNA-1273 (Moderna) | mRNA-1273 (Moderna) | mRNA-1273 (Moderna) | BNT162b2 (Pfizer–BioNTech) | BNT162b2 (Pfizer–BioNTech) | BNT162b2 (Pfizer–BioNTech) | BNT162b2 (Pfizer–BioNTech) | BNT162b2 (Pfizer–BioNTech) | BNT162b2 (Pfizer–BioNTech) | |
| Time between last infusion and first dose of vaccine (days) | 218 | 6 | 384 | 183 | 277 | 84 | 235 | 158 | 279 | 277 | |
| Time between second and third dose of vaccine (days) | 110 | 105 | 98 | 98 | 91 | 91 | 74 | 74 | 94 | 81 | |
| At the time of third dose | |||||||||||
| IgG concentration, g/L | 7·8 | 10·5 | 6·0 | 13·1 | 15·3 | 11·5 | 6·8 | 7·5 | 4·6 | 17·5 | |
| B lymphocyte, cells per μL | 36 | 0 | 20 | 0 | 1 | 0 | 86 | 1 | 81 | 95 | |
| T lymphocyte, cells per μL | 1917 | 740 | 906 | 1310 | 573 | 1227 | 1195 | 1253 | 677 | 581 | |
| CD4 T lymphocyte, cells per μL | 1054 | 551 | 847 | 740 | 354 | 866 | 936 | 868 | 562 | 504 | |
| CD8 T lymphocyte, cells per μL | 792 | 172 | 50 | 525 | 210 | 337 | 244 | 393 | 84 | 86 | |
| Anti-SARS-CoV-2 serology | |||||||||||
| Day of third dose | Positive | Negative | Positive | Positive | Positive | Negative | Positive | Negative | Positive | Positive | |
| 1 month after third dose | Positive | Negative | Positive | Positive | Positive | Negative | Positive | Negative | Positive | Positive | |
| Neutralising antibodies | |||||||||||
| Day of third dose | Negative | Negative | Negative | Positive | Negative | Negative | Negative | Negative | Negative | Negative | |
| 1 month after third dose | Positive | Negative | Negative | Positive | Negative | Negative | Positive | Negative | Positive* | Positive | |
DMARDs=disease-modifying antirheumatic drugs. NA=not applicable.
*
Only for D614G Strain and negative for B.1.351.